Is MRNA or MGX more profitable?

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Metagenomi -384.61% -63.65% -44.52%

Does the media favor MRNA or MGX?

In the previous week, Moderna had 120 more articles in the media than Metagenomi. MarketBeat recorded 123 mentions for Moderna and 3 mentions for Metagenomi. Moderna's average media sentiment score of 0.37 beat Metagenomi's score of 0.36 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 49 Very Positive mention(s) 20 Positive mention(s) 14 Neutral mention(s) 19 Negative mention(s) 16 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PLX or MGX?

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than Metagenomi. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.36 beat Protalix BioTherapeutics' score of 0.24 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ADAG or MGX?

Adagene has higher earnings, but lower revenue than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 24.10 -$17.61M N/A N/A Metagenomi $25.21M 1.81 -$87.87M -$2.49 N/A

Is ADAG or MGX more profitable?

Adagene has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Adagene's return on equity of 0.00% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Metagenomi -384.61% -63.65% -44.52%

Does the media prefer ADAG or MGX?

In the previous week, Metagenomi had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Metagenomi's score of 0.36 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MDWD or MGX more profitable?

MediWound has a net margin of -170.10% compared to Metagenomi's net margin of -384.61%. MediWound's return on equity of -47.24% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -170.10% -47.24% -24.27% Metagenomi -384.61% -63.65% -44.52%

Does the media favor MDWD or MGX?

In the previous week, MediWound had 11 more articles in the media than Metagenomi. MarketBeat recorded 14 mentions for MediWound and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.36 beat MediWound's score of 0.06 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGX or MOLN?

In the previous week, Metagenomi had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Molecular Partners. Metagenomi's average media sentiment score of 0.36 beat Molecular Partners' score of 0.00 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Metagenomi (MGX) Competitors

$1.21 -0.02 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.02 (+1.24%)

As of 06:57 PM Eastern

Compare

MGX vs. MRNA, PLX, ADAG, MDWD, and MOLN

Should you buy Metagenomi stock or one of its competitors? Metagenomi's main competitors and comparable companies include Moderna (MRNA), Protalix BioTherapeutics (PLX), Adagene (ADAG), MediWound (MDWD), and Molecular Partners (MOLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Metagenomi	-384.61%	-63.65%	-44.52%

Moderna currently has a consensus target price of $74.31, indicating a potential downside of 46.50%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 395.87%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	28.52	-$2.82B	-$7.99	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.49	N/A

In the previous week, Moderna had 120 more articles in the media than Metagenomi. MarketBeat recorded 123 mentions for Moderna and 3 mentions for Metagenomi. Moderna's average media sentiment score of 0.37 beat Metagenomi's score of 0.36 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	49 Very Positive mention(s)	20 Positive mention(s)	14 Neutral mention(s)	19 Negative mention(s)	16 Very Negative mention(s)	Neutral
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Moderna beats Metagenomi on 10 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.41	$8.31M	$0.23	10.48
Metagenomi	$25.21M	1.81	-$87.87M	-$2.49	N/A

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than Metagenomi. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.36 beat Protalix BioTherapeutics' score of 0.24 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 397.93%. Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 395.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Protalix BioTherapeutics has a net margin of -21.03% compared to Metagenomi's net margin of -384.61%. Protalix BioTherapeutics' return on equity of -30.89% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Metagenomi	-384.61%	-63.65%	-44.52%

Summary

Protalix BioTherapeutics beats Metagenomi on 11 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Adagene?

Adagene (NASDAQ:ADAG) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Adagene has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Adagene presently has a consensus price target of $10.00, suggesting a potential upside of 156.41%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 395.87%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

9.5% of Adagene shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Metagenomi had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Metagenomi's score of 0.36 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adagene has higher earnings, but lower revenue than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	24.10	-$17.61M	N/A	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.49	N/A

Adagene has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Adagene's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Metagenomi	-384.61%	-63.65%	-44.52%

Summary

Adagene beats Metagenomi on 8 of the 14 factors compared between the two stocks.

How does Metagenomi compare to MediWound?

MediWound (NASDAQ:MDWD) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

MediWound has a net margin of -170.10% compared to Metagenomi's net margin of -384.61%. MediWound's return on equity of -47.24% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Metagenomi	-384.61%	-63.65%	-44.52%

MediWound has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

MediWound has higher earnings, but lower revenue than Metagenomi. MediWound is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	9.85	-$23.88M	-$1.80	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.49	N/A

In the previous week, MediWound had 11 more articles in the media than Metagenomi. MarketBeat recorded 14 mentions for MediWound and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.36 beat MediWound's score of 0.06 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MediWound presently has a consensus target price of $33.00, indicating a potential upside of 153.85%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 395.87%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

MediWound beats Metagenomi on 8 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Molecular Partners?

Metagenomi (NASDAQ:MGX) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Metagenomi currently has a consensus price target of $6.00, indicating a potential upside of 395.87%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 90.34%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts plainly believe Metagenomi is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Molecular Partners has lower revenue, but higher earnings than Metagenomi. Molecular Partners is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.81	-$87.87M	-$2.49	N/A
Molecular Partners	$5.65M	31.45	-$74.41M	-$1.94	N/A

In the previous week, Metagenomi had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Molecular Partners. Metagenomi's average media sentiment score of 0.36 beat Molecular Partners' score of 0.00 indicating that Metagenomi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Metagenomi has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

26.6% of Molecular Partners shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Molecular Partners has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Molecular Partners	N/A	-66.62%	-54.85%

Summary

Metagenomi beats Molecular Partners on 9 of the 15 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.47M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	N/A	11.75	271.38	24.10
Price / Sales	1.81	1,398.89	638.99	90.03
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.29	17.26	11.18	6.40
Net Income	-$87.87M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-0.82%	2.89%	1.98%	0.91%
1 Month Performance	0.41%	9.74%	7.32%	5.10%
1 Year Performance	-37.31%	54.81%	24.76%	16.16%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	3.0752 of 5 stars	$1.21 -1.6%	$6.00 +395.9%	-36.3%	$46.47M	$25.21M	N/A	236	Analyst Downgrade
MRNA Moderna	1.628 of 5 stars	$62.17 -3.6%	$42.13 -32.2%	+434.9%	$24.82B	$2.21B	N/A	4,700	Trending News Analyst Forecast
PLX Protalix BioTherapeutics	2.738 of 5 stars	$2.29 -0.2%	$12.00 +425.2%	+43.4%	$184.11M	$80.62M	N/A	200
ADAG Adagene	2.3025 of 5 stars	$3.88 +1.4%	$10.00 +157.5%	+68.2%	$184.06M	$7.67M	N/A	260
MDWD MediWound	3.2915 of 5 stars	$13.61 +1.6%	$33.00 +142.6%	-24.9%	$174.82M	$16.96M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, PLX, ADAG, MDWD, and MOLN

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to Protalix BioTherapeutics?

Summary

How does Metagenomi compare to Adagene?

Summary

How does Metagenomi compare to MediWound?

Summary

How does Metagenomi compare to Molecular Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, PLX, ADAG, MDWD, and MOLN

How does Metagenomi compare to Moderna?

Is MRNA or MGX more profitable?

Do analysts prefer MRNA or MGX?

Do insiders and institutionals believe in MRNA or MGX?

Which has preferable valuation and earnings, MRNA or MGX?

Does the media favor MRNA or MGX?

Which has more volatility and risk, MRNA or MGX?

Summary

How does Metagenomi compare to Protalix BioTherapeutics?

Which has more risk & volatility, PLX or MGX?

Which has stronger valuation & earnings, PLX or MGX?

Do institutionals & insiders believe in PLX or MGX?

Does the media prefer PLX or MGX?

Do analysts prefer PLX or MGX?

Is PLX or MGX more profitable?

Summary

How does Metagenomi compare to Adagene?

Which has more volatility and risk, ADAG or MGX?

Do analysts recommend ADAG or MGX?

Do institutionals and insiders hold more shares of ADAG or MGX?

Does the media prefer ADAG or MGX?

Which has better earnings & valuation, ADAG or MGX?

Is ADAG or MGX more profitable?

Summary

How does Metagenomi compare to MediWound?

Is MDWD or MGX more profitable?

Which has more volatility and risk, MDWD or MGX?

Which has preferable earnings & valuation, MDWD or MGX?

Does the media favor MDWD or MGX?

Do insiders and institutionals believe in MDWD or MGX?

Do analysts prefer MDWD or MGX?

Summary

How does Metagenomi compare to Molecular Partners?

Do analysts rate MGX or MOLN?

Which has stronger valuation & earnings, MGX or MOLN?

Does the media favor MGX or MOLN?

Which has more risk & volatility, MGX or MOLN?

Do insiders & institutionals believe in MGX or MOLN?

Is MGX or MOLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools